Given detailed understanding of the interaction interface and key residues involved, it is plausible to hypothesize that inhibitors targeting the NAA10–NAA15 interaction could be identified and developed as a novel therapeutic strategy for cancer treatment. This evidence concerns the gene NAA10 and cancer.